There has been little research on kidney disease progression in the past. The GCKD-Study is conducted to better understand the causes, course, risk factors and consequences of progressive kidney insufficiency in order to open up new avenues of targeted diagnostic and therapeutic possibilities.

Many people are affected by kidney insufficiency.  It often takes years to get from the first mild symptoms to advanced stages of kidney impairment and end-stage renal disease.
The GCKD has enrolled a total of 5217 patients with chronic kidney disease (CKD) independent of the underlying cause; 169 nephrologists all aover Germany have helped to achieve this large number.
The objective is to prospectively monitor course and complications over a period of ten years in order to better understand the factors underlying the progression of CKD to end stage renal disease and to better protect future generations, offering a more targeted therapy.

GCKD is designed as one of the largest cohort studies worldwide and among the first ones in Europe to prospectively monitor course and complications of patients with CKD of different origins with sufficient power to understand the relations between biomarkers, course and complications.

FU6 visits have started in April 2016; as of January 9, 2017, data from 1228 patients have already been entered into the central database.